Medtronic (MDT) closed the latest trading day at $90.07, indicating a +0.92% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.41%.

A former Medtronic consultant received an 18-month prison sentence this week for his role in a scheme linked to the $1.6 billion acquisition of an Israeli medical device company in 2018.

Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to ...

(Courtesy of Medtronic) At the time, pacemakers were “crude devices,” with wires coming out of the person ... exclusive U.S.

You're not able to count on it for as long as expected, say experts who call the risk high. Here's who's affected—possibly ...

Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today. Michael Matson’s rating is ...

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. We look at what the results mean for ...

Beese Fulmer Investment Management Inc. cut its position in Medtronic plc (NYSE:MDT – Free Report) by 24.4% during the third ...

Fortitude Family Office LLC purchased a new stake in Medtronic plc (NYSE:MDT – Free Report) during the third quarter, ...

Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation ...